Hu Xian Jun, Sun Xiao Guang, Cheng Jia Yuan, Ma Jie
Department of Cardiovascular Medicine, Chaohu Hospital of Anhui Medical University, Chaohu, China.
These authors contributed equally to this work.
Cardiol Res. 2024 Aug;15(4):246-252. doi: 10.14740/cr1639. Epub 2024 Jul 18.
Non-ST-segment elevation myocardial infarction (NSTEMI) is a common form of coronary artery disease, and its prognosis is influenced by multiple factors. This study aimed to analyze the predictive role of the combined application of cardiac troponin and cardiac function indices in NSTEMI patients' prognosis.
NSTEMI patients were screened and included in the study. Cardiac troponin elevation ratio (cardiac troponin I (cTnI)/upper limit of normal (ULN)) was measured upon admission, and cardiac function was assessed. General clinical data, laboratory parameters, Grace score, New York Heart Association (NYHA) functional class, complications, and mortality data were collected. The correlation between mortality in NSTEMI patients and clinical parameters was analyzed, and a nomogram prediction model for NSTEMI patient mortality was established.
A total of 252 NSTEMI patients were included. Female gender, elevated high-sensitivity C-reactive protein (H-CRP), left ventricular ejection fraction (LVEF) < 50%, NYHA class III and IV, and cTnI/ULN elevation by 36.25-fold were significantly independently associated with mortality outcomes. Multifactorial logistic analysis indicated that these indices remained associated with mortality. A nomogram model predicting NSTEMI patient mortality was constructed using these indices, with an area under the curve (AUC) of 0.911, sensitivity of 97.5%, and specificity of 72.8%. This predictive model outperformed the Grace score (AUC = 0.840).
In NSTEMI patients, a 36.25-fold increase in cTnI/ULN, coupled with NYHA class III and IV, independently predicted prognosis. We developed a nomogram model integrating cTnI/ULN and cardiac function indices, aiding clinicians in assessing risk and implementing early interventions for improved outcomes.
非ST段抬高型心肌梗死(NSTEMI)是冠状动脉疾病的一种常见形式,其预后受多种因素影响。本研究旨在分析心肌肌钙蛋白与心功能指标联合应用对NSTEMI患者预后的预测作用。
筛选NSTEMI患者并纳入研究。入院时测量心肌肌钙蛋白升高倍数(心肌肌钙蛋白I(cTnI)/正常上限(ULN)),并评估心功能。收集一般临床资料、实验室参数、Grace评分、纽约心脏协会(NYHA)心功能分级、并发症及死亡率数据。分析NSTEMI患者死亡率与临床参数之间的相关性,并建立NSTEMI患者死亡率的列线图预测模型。
共纳入252例NSTEMI患者。女性、高敏C反应蛋白(H-CRP)升高、左心室射血分数(LVEF)<50%、NYHA III级和IV级以及cTnI/ULN升高36.25倍与死亡结局显著独立相关。多因素logistic分析表明,这些指标仍与死亡率相关。使用这些指标构建了预测NSTEMI患者死亡率的列线图模型,曲线下面积(AUC)为0.911,敏感性为97.5%,特异性为72.8%。该预测模型优于Grace评分(AUC = 0.840)。
在NSTEMI患者中,cTnI/ULN升高36.25倍,联合NYHA III级和IV级,可独立预测预后。我们开发了一个整合cTnI/ULN和心功能指标的列线图模型,有助于临床医生评估风险并实施早期干预以改善预后。